United Therapeutics Corp (FRA:UTH)
€ 245.3 4.6 (1.91%) Market Cap: 10.88 Bil Enterprise Value: 8.92 Bil PE Ratio: 12.50 PB Ratio: 2.19 GF Score: 89/100

United Therapeutics Corp at UBS BioPharma Conference Transcript

Nov 08, 2023 / 03:00PM GMT
Release Date Price: €213.7 (+1.23%)
Unidentified Participant

Yes. And with me today, our next company, United Therapeutics, from where we have Pat Poisson, who is the Executive Vice President of Tech Ops. How are you doing today?

Patrick Poisson
United Therapeutics Corporation - Executive VP of Technical Operations

Good, good.

Questions & Answers

Unidentified Participant

Thanks for joining us. It's a real pleasure. So I wanted to understand the therapeutic story, a little bit in more detail today in the fireside chat. We have 25 minutes and ask more questions about the manufacturing with which you are the closest to in the organization. So I would love to get your perspective maybe perhaps we can start off by just getting like a high-level background about United Therapeutics for investors that might not be familiar with it.

Patrick Poisson
United Therapeutics Corporation - Executive VP of Technical Operations

Sure, sure. So. like to thank UBS for having us down here. Before I go into any details, I just

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot